NADAC acquisition cost data for INVOKAMET XR 150-1,000 MG TAB. This is a brand-name medication — generic alternatives may be available at lower prices.
| Generic Name | canagliflozin and metformin hydrochloride |
| Brand Name | INVOKAMET XR |
| Manufacturer | Janssen Pharmaceuticals, Inc. |
| Dosage Form | TABLET, FILM COATED, EXTENDED RELEASE |
| Route | ORAL |
| Pharmacologic Class | Biguanide |
| Product Type | HUMAN PRESCRIPTION DRUG |
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 50458094301 | $9.09 | 2022-01-19 | Rx |
| 50458094301 | $9.09 | 2022-01-19 | Rx |
| 50458094301 | $9.09 | 2022-01-19 | Rx |
| 50458094301 | $9.09 | 2022-01-19 | Rx |
| 50458094301 | $9.09 | 2022-01-19 | Rx |
| 50458094301 | $9.09 | 2022-01-19 | Rx |
| 50458094301 | $9.09 | 2022-01-19 | Rx |
| 50458094301 | $9.09 | 2022-01-19 | Rx |
| 50458094301 | $9.09 | 2022-01-19 | Rx |
| 50458094301 | $9.09 | 2022-01-19 | Rx |
Generic: Canagliflozin/Metformin HCl | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $17.6M | 24,693 | 6,224 | $8.29 |
| 2020 | $22.1M | 27,784 | 6,056 | $8.64 |
| 2021 | $16.5M | 19,453 | 4,699 | $9.02 |
| 2022 | $16.2M | 17,225 | 3,903 | $9.69 |
| 2023 | $13.1M | 12,508 | 3,060 | $10.25 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.
Explore More Data Tools
For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.